The real cost of SAHPRA delays

When people talk about regulatory delay at SAHPRA, they reach instinctively for the timeline: how many months a dossier sits in the queue. It is the wrong unit. A delay is not a duration; it is a cost, and the cost compounds in places the timeline never shows.

Start with the obvious one: revenue deferred is revenue discounted. A product that reaches market a year late does not simply earn a year less, it earns under worse conditions, with competitors closer and pricing power eroded. Then add the quieter costs. Capital is tied up in inventory and registration spend with no offsetting income. Commercial teams are hired and idle, or not hired and unavailable when approval finally lands. Partnerships stall because no one will commit to a launch date that depends on a queue.

The reason this matters commercially, not just operationally, is that the cost is unevenly distributed. A large multinational can absorb a delay; it is a line item. A smaller sponsor, or a first African entry, often cannot, and the delay quietly decides which products reach patients here at all. That selection effect is the part worth understanding. The opportunity sits with whoever can shorten, de-risk or simply price the delay correctly, because everyone else is still measuring it in months.

This is a working draft. The full piece is in progress.